Brief Report - (2025) Volume 10, Issue 6
Received: 01-Dec-2025, Manuscript No. cgj-26-186547;
Editor assigned: 03-Dec-2026, Pre QC No. P-186547;
Reviewed: 17-Dec-2025, QC No. Q-186547;
Revised: 22-Dec-2025, Manuscript No. R-186547;
Published:
29-Dec-2025
, DOI: 10.37421/2952-8518.2025.10.340
Citation: Clarke, Jonathan E.. ”Gut Microbiome’s Role in Health and Disease.” Clin Gastroenterol J 10 (2025):340.
Copyright: © 2025 Clarke E. Jonathan This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Gastrointestinal disorders represent a significant global health challenge, with a growing understanding of the complex interplay between the host and its resident microbial communities. The gastrointestinal microbiome, a vast ecosystem of bacteria, viruses, fungi, and archaea, plays a pivotal role in maintaining host health and is increasingly implicated in the pathogenesis of numerous diseases. Dysbiosis, an imbalance in this microbial community, has emerged as a key factor contributing to various gastrointestinal ailments, driving extensive research into its mechanisms and therapeutic potential. Gastrointestinal microbiome dysbiosis plays a significant role in the pathogenesis and progression of various gastrointestinal disorders. Alterations in microbial composition and function are linked to inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), and even colorectal cancer. Understanding these microbial shifts can lead to novel diagnostic biomarkers and therapeutic strategies, including targeted probiotics, prebiotics, and fecal microbiota transplantation. [1] Specific microbial profiles are associated with different subtypes of irritable bowel syndrome (IBS). For instance, small intestinal bacterial overgrowth (SIBO) is a common finding in some IBS patients, and its correction can alleviate symptoms. This highlights the importance of tailoring treatment based on an individual's gut microbiome composition. [2] The gut microbiome influences colorectal cancer (CRC) development through various mechanisms, including the production of pro-inflammatory metabolites and modulation of immune responses. Certain bacterial species have been identified as potential drivers of CRC, while others may exert protective effects. Targeting the microbiome could offer a new avenue for CRC prevention and treatment. [3] Fecal microbiota transplantation (FMT) has emerged as a highly effective treatment for recurrent Clostridioides difficile infection (CDI). Its success in restoring a healthy gut ecosystem suggests its potential for treating other microbiome-associated disorders. [4] The intricate interplay between the gut microbiome and the host immune system is crucial for maintaining gastrointestinal homeostasis. Dysbiosis can lead to chronic inflammation, a hallmark of many GI diseases. [5] Dietary interventions, such as the Mediterranean diet, can positively influence the gut microbiome composition and function, leading to improved gastrointestinal health outcomes. This underscores the therapeutic potential of personalized nutrition strategies. [6] The gut microbiome's influence extends beyond the gastrointestinal tract, impacting systemic diseases through the gut-brain axis and metabolic pathways. Dysbiosis has been implicated in neurological and metabolic disorders. [7] Antibiotic therapy can profoundly disrupt the gut microbiome, leading to dysbiosis and increasing the risk of opportunistic infections. Judicious use of antibiotics and strategies to mitigate their impact on the microbiome are essential. [8] Probiotics and prebiotics hold promise as interventions to restore gut microbial balance and improve GI health. However, more research is needed to define optimal strains and dosages for specific conditions. [9] The gut microbiome's role in non-alcoholic fatty liver disease (NAFLD) is increasingly recognized. Dysbiosis can contribute to liver inflammation and fibrosis through altered bile acid metabolism and increased gut permeability. [10]
The gastrointestinal tract harbors a complex and dynamic microbial ecosystem, the gut microbiome, which is fundamental to host physiology and health. Imbalances in this intricate community, termed dysbiosis, are increasingly recognized as critical drivers in the pathogenesis and progression of a wide spectrum of gastrointestinal disorders. Understanding these microbial alterations is pivotal for developing novel diagnostic tools and therapeutic interventions tailored to restore a healthy gut environment. Gastrointestinal microbiome dysbiosis plays a significant role in the pathogenesis and progression of various gastrointestinal disorders. Alterations in microbial composition and function are linked to inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), and even colorectal cancer. Understanding these microbial shifts can lead to novel diagnostic biomarkers and therapeutic strategies, including targeted probiotics, prebiotics, and fecal microbiota transplantation. [1] Specific microbial profiles are associated with different subtypes of irritable bowel syndrome (IBS). For instance, small intestinal bacterial overgrowth (SIBO) is a common finding in some IBS patients, and its correction can alleviate symptoms. This highlights the importance of tailoring treatment based on an individual's gut microbiome composition. [2] The gut microbiome influences colorectal cancer (CRC) development through various mechanisms, including the production of pro-inflammatory metabolites and modulation of immune responses. Certain bacterial species have been identified as potential drivers of CRC, while others may exert protective effects. Targeting the microbiome could offer a new avenue for CRC prevention and treatment. [3] Fecal microbiota transplantation (FMT) has emerged as a highly effective treatment for recurrent Clostridioides difficile infection (CDI). Its success in restoring a healthy gut ecosystem suggests its potential for treating other microbiome-associated disorders. [4] The intricate interplay between the gut microbiome and the host immune system is crucial for maintaining gastrointestinal homeostasis. Dysbiosis can lead to chronic inflammation, a hallmark of many GI diseases. [5] Dietary interventions, such as the Mediterranean diet, can positively influence the gut microbiome composition and function, leading to improved gastrointestinal health outcomes. This underscores the therapeutic potential of personalized nutrition strategies. [6] The gut microbiome's influence extends beyond the gastrointestinal tract, impacting systemic diseases through the gut-brain axis and metabolic pathways. Dysbiosis has been implicated in neurological and metabolic disorders. [7] Antibiotic therapy can profoundly disrupt the gut microbiome, leading to dysbiosis and increasing the risk of opportunistic infections. Judicious use of antibiotics and strategies to mitigate their impact on the microbiome are essential. [8] Probiotics and prebiotics hold promise as interventions to restore gut microbial balance and improve GI health. However, more research is needed to define optimal strains and dosages for specific conditions. [9] The gut microbiome's role in non-alcoholic fatty liver disease (NAFLD) is increasingly recognized. Dysbiosis can contribute to liver inflammation and fibrosis through altered bile acid metabolism and increased gut permeability. [10]
The gastrointestinal microbiome is crucial for health, and its dysbiosis is linked to various gastrointestinal disorders including IBD, IBS, and colorectal cancer. Specific microbial profiles are associated with IBS subtypes, and interventions like FMT are effective for CDI, suggesting broader therapeutic potential. The microbiome interacts with the immune system, influencing inflammation and maintaining homeostasis. Dietary changes can positively modulate the microbiome, improving GI health. Beyond the gut, microbiome imbalances affect systemic diseases via the gut-brain axis and metabolic pathways. Antibiotic use can disrupt the microbiome, increasing infection risk. Probiotics and prebiotics show promise for restoring balance, though more research is needed. The microbiome also plays a role in NAFLD, contributing to liver inflammation.
None
None
Clinical Gastroenterology Journal received 33 citations as per Google Scholar report
